Skip to content

Alligator Bioscience

  •  
    • Se
  • Startpage
  • About Alligator
    • Board of Directors
    • Senior Management
    • Career
  • Research and development
    • Immunotherapy of cancer
    • Pipeline
      • Mitazalimab
      • Neo-X-PrimeTM
      • ALG.APV-527
      • ATOR-1017
      • Research projects
    • Scientific publications
    • Technology platform
      • Alligator-GOLD®
      • Alligator-FABTM
      • FIND®
    • Scientific advisors
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination Committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and owner information
    • Sharegraph
    • Analysts
    • Preferential Rights Issue Q2 2023
    • Preferential Rights Issue Q4 2021
    • Preferential Rights Issue Q1 2021
    • IPO
    • Financial reports
      • Interim reports
      • Year End Reports
      • Annual reports
    • Financial calendar
    • Presentations
  • Business Development
  • News
  • Press releases
  • Contact
  • Events

  1. Startpage
  2. News
Key downloads
Alligator Bioscience AB reports full year financial results for 2022 and for Q4 2022 and provides a business updateAlligator Bioscience AB reports financial results for the first 9 months of the year and for Q3 2022 and provides a business updateAlligator Bioscience AB reports H1 2022 and Q2 2022 financial results and provides a business updateBulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2022Interim report January–March 2022
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
All IRRegulatoryReport
View as grid View as list
2017-12-04

Alligator Bioscience expands management team

Appointment of Chief Medical Officer and VP Discovery Lund, Sweden, 4 December 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biot ...
Continue reading
2017-11-21

Alligator Bioscience AB presents at Redeye Life Science Seminar 24 November 2017

Lund, Sweden, 21 November 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceu ...
Continue reading
2017-11-13

Nomination Committee appointed in respect of AGM 2018 in Alligator Bioscience AB

Lund, Sweden, 13 November, 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmace ...
Continue reading
2017-11-07
Regulatory

Results from Alligator Bioscience’s clinical phase I study support further clinical development of ADC-1013

Lund, Sweden, 7 November 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceut ...
Continue reading
2017-10-25
Regulatory

Alligator Bioscience AB Interim Report January-September 2017

Three important collaborations in place. Results in November from ADC-1013 clinical phase I study. Significant events, July-September • Apte ...
Continue reading
2017-10-24
Regulatory

Alligator Bioscience Aptevo Therapeutics: Tumor antigen 5T4 associated with many forms of solid tumors identified as the second target for ALG.APV-527

ALG.APV-527 – A novel bispecific antibody candidate being developed by Alligator Bioscience and Aptevo Therapeutics. Engineered to Eng ...
Continue reading
2017-09-21
Regulatory

Alligator Bioscience to present ADC-1013 intratumoral clinical phase I study results at SITC in November 2017

Lund, Sweden, September 21, 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmac ...
Continue reading
2017-09-13
Regulatory

Alligator Bioscience signs immunotherapy research collaboration agreement for 4-1BB

Research team to be led by Professor Ignacio Melero, Center for Applied Medical Research (CIMA) and Clínica Universidad de Navarra, Spain Lu ...
Continue reading
2017-08-23
Regulatory

Alligator Bioscience AB (Nasdaq Stockholm; ATORX) Interim report January – June 2017

“We have advanced our project pipeline significantly during the second quarter. The immuno-oncology antibody ATOR-1017 moved into pre-clinic ...
Continue reading

Posts navigation

Older posts
  1. Startpage
  2. News
About Alligator

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase 2 studies and beyond.

Alligator Bioscience has global headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm (ticker: ATORX).

Links
  • About Alligator
  • R&D
  • Corporate governance
  • Investors
  • News
  • Business Development
  • Privacy Policy
Contact us

Alligator Bioscience AB Medicon Village Scheelevägen 2 SE-223 81 Lund Sweden

Phone:
+ 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com
bd@alligatorbioscience.com

Follow us

  

Email subscription

Subscribe to get our pressreleases and investor alerts by email from Alligator Bioscience.

Subscribe

  • © Copyright 2019 – Alligator Bioscience AB

  • Privacy Policy | Use of Cookies |  Change your cookie settings here.

  • Disclaimer Market data could be delayed. Delivered by Modular Finance.

Cookies
We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.
Settings Accept all
Cookies
Do your settings below. Or read our cookie policy.
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all